Zafgen (ZFGN) Tops Q4 EPS by 36c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. HALO
7. BBIO
8. SPY
9. RCKT
10. CRWV

Go back to Zafgen (ZFGN) Tops Q4 EPS by 36c

Zafgen Reports Fourth Quarter and Full Year 2014 Financial Results

March 19, 2015 4:00 PM EDT

Quarter and Full Year Highlighted by Further Progress in Advancing Beloranib Clinical Development Program

Company to Report Data from Ongoing Clinical Trials in Late 2015/Early 2016

Enters 2015 with Pro-Forma Cash and Marketable Securities of $245 Million Following Recent Follow-on Offering

BOSTON, March 19, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its fourth quarter and full year 2014 financial results.

Zafgen 2014 and Early 2015... More